Pharming Group N.V. (PHAR)
USD 7.69
(0.52%)
USD 7.69
(0.52%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 462.85 Million USD | 8.7% |
| 2022 | 425.79 Million USD | 7.28% |
| 2021 | 396.9 Million EUR | -5.3% |
| 2020 | 419.11 Million EUR | 63.95% |
| 2019 | 255.63 Million EUR | 4.15% |
| 2018 | 245.44 Million EUR | 23.11% |
| 2017 | 199.37 Million EUR | 49.53% |
| 2016 | 133.33 Million EUR | 111.45% |
| 2015 | 63.05 Million EUR | -6.93% |
| 2014 | 67.75 Million EUR | 56.22% |
| 2013 | 43.37 Million EUR | 94.69% |
| 2012 | 22.27 Million EUR | -30.4% |
| 2011 | 32 Million EUR | -35.46% |
| 2010 | 49.59 Million EUR | -38.06% |
| 2009 | 80.06 Million EUR | -14.28% |
| 2008 | 93.4 Million EUR | -43.98% |
| 2007 | 166.71 Million EUR | 59.74% |
| 2006 | 104.36 Million EUR | 154.78% |
| 2005 | 40.96 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 415.92 Million USD | -5.83% |
| 2024 Q3 | 425.51 Million USD | 2.3% |
| 2024 Q1 | 441.66 Million USD | -6.22% |
| 2023 Q3 | 436.46 Million USD | 1.55% |
| 2023 Q4 | 470.95 Million USD | 7.9% |
| 2023 FY | 462.85 Million USD | 8.7% |
| 2023 Q1 | 422.99 Million USD | -0.66% |
| 2023 Q2 | 429.8 Million USD | 1.61% |
| 2022 Q1 | 392.79 Million USD | 12.05% |
| 2022 Q2 | 393.89 Million USD | 0.28% |
| 2022 Q3 | 382.32 Million USD | -2.94% |
| 2022 Q4 | 425.79 Million USD | 11.37% |
| 2022 FY | 425.79 Million USD | 7.28% |
| 2021 Q1 | 408.56 Million EUR | -2.52% |
| 2021 FY | 396.9 Million EUR | -5.3% |
| 2021 Q4 | 350.55 Million EUR | -12.56% |
| 2021 Q3 | 400.9 Million EUR | -2.7% |
| 2021 Q2 | 412.02 Million EUR | 0.85% |
| 2020 Q1 | 335.22 Million EUR | 31.13% |
| 2020 Q4 | 419.11 Million EUR | 11.78% |
| 2020 Q3 | 374.93 Million EUR | 5.13% |
| 2020 FY | 419.11 Million EUR | 63.95% |
| 2020 Q2 | 356.64 Million EUR | 6.39% |
| 2019 Q3 | 241.59 Million EUR | 3.25% |
| 2019 Q4 | 255.63 Million EUR | 5.81% |
| 2019 Q2 | 233.98 Million EUR | 4.41% |
| 2019 FY | 255.63 Million EUR | 4.15% |
| 2019 Q1 | 224.1 Million EUR | -8.69% |
| 2018 FY | 245.44 Million EUR | 23.11% |
| 2018 Q4 | 245.44 Million EUR | 9.61% |
| 2018 Q3 | 223.93 Million EUR | 6.79% |
| 2018 Q2 | 209.69 Million EUR | -0.35% |
| 2018 Q1 | 210.43 Million EUR | 5.54% |
| 2017 Q3 | 164.33 Million EUR | 13.14% |
| 2017 Q4 | 199.37 Million EUR | 21.33% |
| 2017 Q2 | 145.24 Million EUR | 3.41% |
| 2017 Q1 | 140.45 Million EUR | 5.34% |
| 2017 FY | 199.37 Million EUR | 49.53% |
| 2016 Q2 | 59.69 Million EUR | -5.56% |
| 2016 FY | 133.33 Million EUR | 111.45% |
| 2016 Q4 | 133.33 Million EUR | 143.27% |
| 2016 Q3 | 54.81 Million EUR | -8.18% |
| 2016 Q1 | 63.2 Million EUR | 0.24% |
| 2015 FY | 63.05 Million EUR | -6.93% |
| 2015 Q3 | 69.94 Million EUR | 24.32% |
| 2015 Q4 | 63.05 Million EUR | -9.84% |
| 2015 Q1 | 58.2 Million EUR | -14.09% |
| 2015 Q2 | 56.25 Million EUR | -3.35% |
| 2014 FY | 67.75 Million EUR | 56.22% |
| 2014 Q4 | 67.75 Million EUR | 30.99% |
| 2014 Q3 | 51.72 Million EUR | -7.52% |
| 2014 Q2 | 55.92 Million EUR | 22.47% |
| 2014 Q1 | 45.66 Million EUR | 5.29% |
| 2013 Q3 | 32 Million EUR | -14.35% |
| 2013 FY | 43.37 Million EUR | 94.69% |
| 2013 Q1 | 37.63 Million EUR | 68.94% |
| 2013 Q2 | 37.36 Million EUR | -0.71% |
| 2013 Q4 | 43.37 Million EUR | 35.51% |
| 2012 Q1 | 36.95 Million EUR | 15.45% |
| 2012 Q4 | 22.27 Million EUR | 10.86% |
| 2012 Q3 | 20.09 Million EUR | 0.0% |
| 2012 FY | 22.27 Million EUR | -30.4% |
| 2011 Q3 | 37.68 Million EUR | -12.62% |
| 2011 Q4 | 32 Million EUR | -15.07% |
| 2011 FY | 32 Million EUR | -35.46% |
| 2011 Q1 | 46.4 Million EUR | -6.43% |
| 2011 Q2 | 43.12 Million EUR | -7.06% |
| 2010 FY | 49.59 Million EUR | -38.06% |
| 2010 Q2 | 87.86 Million EUR | 6.59% |
| 2010 Q1 | 82.43 Million EUR | 2.96% |
| 2010 Q3 | 74.07 Million EUR | -15.7% |
| 2010 Q4 | 49.59 Million EUR | -33.05% |
| 2009 FY | 80.06 Million EUR | -14.28% |
| 2009 Q4 | 80.06 Million EUR | 0.0% |
| 2008 FY | 93.4 Million EUR | -43.98% |
| 2007 FY | 166.71 Million EUR | 59.74% |
| 2006 FY | 104.36 Million EUR | 154.78% |
| 2005 FY | 40.96 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 68.896% |
| Alkermes plc | 2.13 Billion USD | 78.333% |
| Agenus Inc. | 313.91 Million USD | -47.447% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 87.915% |
| Aptorum Group Limited | 20.64 Million USD | -2142.5% |
| Ardelyx, Inc. | 297.57 Million USD | -55.54% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | 39.54% |
| Bicycle Therapeutics plc | 595.34 Million USD | 22.254% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -528.007% |
| ChromaDex Corporation | 54.96 Million USD | -742.104% |
| Chimerix, Inc. | 212.77 Million USD | -117.533% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1537.124% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -4.963% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 79.24% |
| Precision BioSciences, Inc. | 159.78 Million USD | -189.68% |
| Dyadic International, Inc. | 8.21 Million USD | -5531.351% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -1358.267% |
| Fortress Biotech, Inc. | 167.52 Million USD | -176.288% |
| Lantern Pharma Inc. | 43.64 Million USD | -960.434% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -186.886% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -3090.634% |
| Incyte Corporation | 6.78 Billion USD | 93.175% |
| IO Biotech, Inc. | 150.71 Million USD | -207.099% |
| Jaguar Health, Inc. | 50.76 Million USD | -811.794% |
| Novavax, Inc. | 1.85 Billion USD | 75.053% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -21.673% |
| Opthea Limited | 188.79 Million USD | -145.167% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 44.44% |
| ContextLogic Inc. | 423 Million USD | -9.422% |
| MiMedx Group, Inc. | 239.04 Million USD | -93.625% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -166.428% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -8853.206% |
| NextCure, Inc. | 129.41 Million USD | -257.643% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -757.963% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -1160.187% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -1332.94% |
| Vaxcyte, Inc. | 1.4 Billion USD | 67.125% |
| PDS Biotechnology Corporation | 59.39 Million USD | -679.346% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | 27.741% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1096.624% |
| Avidity Biosciences, Inc. | 628.55 Million USD | 26.362% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2345.899% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -2345.899% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -179.975% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -922.046% |
| Acelyrin, Inc. | 742.69 Million USD | 37.679% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -6927.289% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -7128.705% |
| Summit Therapeutics Inc. | 202.94 Million USD | -128.064% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -522.333% |
| Senti Biosciences, Inc. | 119.48 Million USD | -287.377% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -102.702% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -175.223% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -5501.525% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -9595.779% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | 1.351% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -274.317% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -68.342% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 2.112% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -4480.445% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -115.777% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -40782.42% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -11.843% |
| Immix Biopharma, Inc. | 19.92 Million USD | -2222.963% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -25.087% |
| MEI Pharma, Inc. | 41.37 Million USD | -1018.68% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -1328.297% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -35.815% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -294.842% |
| Fortress Biotech, Inc. | 167.52 Million USD | -176.288% |
| Precigen, Inc. | 151.04 Million USD | -206.439% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -1260.615% |
| AlloVir, Inc. | 190.79 Million USD | -142.591% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -22.952% |
| Fate Therapeutics, Inc. | 506.21 Million USD | 8.566% |
| ImmuCell Corporation | 43.8 Million USD | -956.549% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | 28.717% |
| Onconetix, Inc. | 88.82 Million USD | -421.106% |
| PureTech Health plc | 693.97 Million USD | 33.304% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -373.823% |
| Elevation Oncology, Inc. | 89.09 Million USD | -419.529% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -7362.98% |
| Seer, Inc. | 436.26 Million USD | -6.094% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -467.244% |
| Innoviva, Inc. | 1.24 Billion USD | 62.778% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -249.527% |
| ESSA Pharma Inc. | 149.12 Million USD | -210.386% |
| GlycoMimetics, Inc. | 45.31 Million USD | -921.381% |
| GT Biopharma, Inc. | 14.1 Million USD | -3180.559% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -50.329% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -91.497% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | 1.918% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -812.981% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -386.13% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -73184.166% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | 18.273% |
| Aptose Biosciences Inc. | 12.92 Million USD | -3481.756% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -1993.009% |
| Soligenix, Inc. | 9.79 Million USD | -4624.289% |
| Century Therapeutics, Inc. | 360.69 Million USD | -28.324% |
| Kura Oncology, Inc. | 448.93 Million USD | -3.1% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -70.074% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -2576.23% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -317.319% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -125.616% |
| Autolus Therapeutics plc | 375.38 Million USD | -23.302% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -83.938% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -30.314% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -842.062% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | 29.991% |
| GRI Bio, Inc. | 2.95 Million USD | -15558.119% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -4264.395% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -171.445% |
| IGM Biosciences, Inc. | 423.41 Million USD | -9.316% |
| INmune Bio, Inc. | 57 Million USD | -712.01% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -108.019% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -451.402% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1672.242% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -6624.406% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -515.285% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -214.315% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -179.663% |
| Coherus BioSciences, Inc. | 629.6 Million USD | 26.485% |
| Verastem, Inc. | 149.71 Million USD | -209.151% |
| Abeona Therapeutics Inc. | 64 Million USD | -623.187% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | 9.626% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -199.665% |
| Histogen Inc. | 19.07 Million USD | -2326.75% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -1943.49% |
| Surrozen, Inc. | 46.08 Million USD | -904.457% |
| Organovo Holdings, Inc. | 6.34 Million USD | -7190.187% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10642.512% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -221.367% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -3821.827% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -514.941% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -5333.037% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -27.519% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -2457.996% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -7.79% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -3570.031% |
| Apollomics, Inc. | 55.38 Million USD | -735.673% |
| Amarin Corporation plc | 831.68 Million USD | 44.347% |
| Mesoblast Limited | 669.15 Million USD | 30.83% |
| Turnstone Biologics Corp. | 112.81 Million USD | -310.277% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | 19.61% |
| Synaptogenix, Inc. | 31.11 Million USD | -1387.623% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -3698.867% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | 15.547% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7782.041% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -6201.484% |
| Exelixis, Inc. | 2.94 Billion USD | 84.269% |
| Better Therapeutics, Inc. | 22.94 Million USD | -1917.408% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -26.97% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 41.317% |
| NLS Pharmaceutics AG | 1.84 Million USD | -24964.644% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -5701.168% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -3049.738% |
| Gritstone bio, Inc. | 177.76 Million USD | -160.368% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -385.274% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -2491.238% |
| Avid Bioservices, Inc. | 336.55 Million USD | -37.526% |
| Insmed Incorporated | 1.32 Billion USD | 65.195% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -4707.202% |
| MediWound Ltd. | 66.45 Million USD | -596.45% |
| OmniAb, Inc. | 401.98 Million USD | -15.142% |
| Alector, Inc. | 621.82 Million USD | 25.565% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -29.073% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -8506.434% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -716.436% |
| Zai Lab Limited | 1.03 Billion USD | 55.336% |
| Revance Therapeutics, Inc. | 478.45 Million USD | 3.261% |
| Aura Biosciences, Inc. | 255.07 Million USD | -81.458% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | 38.289% |
| Immunic, Inc. | 54.29 Million USD | -752.417% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -73.859% |
| Veracyte, Inc. | 1.13 Billion USD | 59.321% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -3814.933% |
| FibroGen, Inc. | 423.52 Million USD | -9.285% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13075.463% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -9671.851% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -8424.834% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 95.938% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -5156.718% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | 10.552% |
| TG Therapeutics, Inc. | 329.58 Million USD | -40.435% |
| Galecto, Inc. | 38.22 Million USD | -1110.804% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -1514.081% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 89.377% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -96.621% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -1763.191% |
| XBiotech Inc. | 227.24 Million USD | -103.682% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -385.274% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -224.582% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -61.885% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -261.975% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -21.166% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 68.957% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -26.864% |
| Vaxxinity, Inc. | 44.35 Million USD | -943.569% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | 10.466% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -2387.215% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -51.731% |
| NexImmune, Inc. | 8.59 Million USD | -5285.813% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -4219.606% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -2602.42% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.601% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -1989.528% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -117895.233% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -167.038% |
| Ainos, Inc. | 31.84 Million USD | -1353.605% |
| Pluri Inc. | 39.52 Million USD | -1070.982% |
| Prothena Corporation plc | 696.38 Million USD | 33.534% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -63.775% |
| Celularity Inc. | 143.88 Million USD | -221.674% |
| Rallybio Corporation | 115.62 Million USD | -300.323% |
| Cue Biopharma, Inc. | 61.53 Million USD | -652.241% |
| MeiraGTx Holdings plc | 458.16 Million USD | -1.023% |
| Omeros Corporation | 378.26 Million USD | -22.361% |
| Humacyte, Inc. | 128.22 Million USD | -260.976% |
| Immunocore Holdings plc | 597 Million USD | 22.47% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -1380.706% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -575.403% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 55.887% |
| CalciMedica, Inc. | 12.18 Million USD | -3698.556% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -82.477% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -170.821% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -48.811% |
| Sana Biotechnology, Inc. | 565.29 Million USD | 18.122% |
| Pulmatrix, Inc. | 33.95 Million USD | -1263.019% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -1605.054% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -228.596% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 64.423% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -255.525% |
| Cytokinetics, Incorporated | 824.31 Million USD | 43.85% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -2091.232% |
| Nutriband Inc. | 7.51 Million USD | -6057.304% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -486.232% |
| Vor Biopharma Inc. | 209.82 Million USD | -120.587% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 93.591% |
| Evogene Ltd. | 51.1 Million USD | -805.763% |
| ProKidney Corp. | 420.55 Million USD | -10.059% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -744.116% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -4761.77% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | 15.287% |
| CorMedix Inc. | 82.05 Million USD | -464.044% |
| BioLineRx Ltd. | 63.92 Million USD | -624.058% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -14.976% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -1541.326% |
| Atai Life Sciences N.V. | 293.47 Million USD | -57.713% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -183.734% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -263.256% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | 17.646% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -378.555% |
| MediciNova, Inc. | 66.26 Million USD | -598.437% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -426.281% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10272.392% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4885.921% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 21.315% |
| Biomea Fusion, Inc. | 199.92 Million USD | -131.512% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 75.68% |
| Mereo BioPharma Group plc | 66.49 Million USD | -596.032% |
| Cullinan Oncology, Inc. | 485.09 Million USD | 4.585% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | 24.479% |
| Absci Corporation | 234.48 Million USD | -97.396% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6227.464% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -36.177% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -180.378% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | 12.059% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -66.678% |
| Allakos Inc. | 243.61 Million USD | -89.998% |
| Imunon, Inc. | 21.91 Million USD | -2011.746% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -79.614% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 25.528% |
| BioAtla, Inc. | 119.65 Million USD | -286.814% |
| NLS Pharmaceutics AG | 1.84 Million USD | -24964.644% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -14274.348% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | 27.998% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -382.466% |
| XOMA Corporation | 234.3 Million USD | -97.547% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -109.214% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -267.8% |
| aTyr Pharma, Inc. | 122.06 Million USD | -279.18% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -200.744% |
| Akero Therapeutics, Inc. | 580.27 Million USD | 20.235% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | 5.622% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -318.99% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -2953.618% |
| Akari Therapeutics, Plc | 4.35 Million USD | -10528.106% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2616.705% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 73.296% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -14908.304% |
| UroGen Pharma Ltd. | 178.31 Million USD | -159.577% |
| Sutro Biopharma, Inc. | 470.73 Million USD | 1.674% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -83189.816% |
| Orgenesis Inc. | 14.55 Million USD | -3080.69% |
| Entera Bio Ltd. | 11.76 Million USD | -3834.161% |
| GH Research PLC | 226.3 Million USD | -104.531% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -746.261% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -330.818% |
| Xencor, Inc. | 952.69 Million USD | 51.416% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -5846.398% |
| Replimune Group, Inc. | 487.72 Million USD | 5.099% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -5634.716% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | 28.62% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -14908.304% |
| Portage Biotech Inc. | 7.77 Million USD | -5850.045% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -10272.392% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -67.128% |
| OncoCyte Corporation | 74.89 Million USD | -518.029% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -22664.267% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -7898.662% |
| Purple Biotech Ltd. | 44.3 Million USD | -944.77% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -1256.309% |
| scPharmaceuticals Inc. | 94.47 Million USD | -389.901% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -2465.005% |
| HilleVax, Inc. | 344.43 Million USD | -34.381% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -14473.489% |
| Tharimmune, Inc. | 10.94 Million USD | -4128.37% |
| Genprex, Inc. | 10.67 Million USD | -4237.66% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | 6.719% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -380.877% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -18978.895% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -11011.765% |
| OKYO Pharma Limited | 1.54 Million USD | -29930.806% |
| Savara Inc. | 177.56 Million USD | -160.669% |
| Curis, Inc. | 77.28 Million USD | -498.916% |
| Daré Bioscience, Inc. | 21.28 Million USD | -2074.839% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -623.788% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -5624.14% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -2289.417% |
| BeiGene, Ltd. | 5.8 Billion USD | 92.027% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -3703.55% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 77.839% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -29.307% |
| Erasca, Inc. | 395.29 Million USD | -17.09% |
| bluebird bio, Inc. | 619.16 Million USD | 25.245% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10605.864% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 93.235% |
| DBV Technologies S.A. | 182.98 Million USD | -152.945% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -10605.864% |
| Moderna, Inc. | 18.42 Billion USD | 97.488% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -2440.781% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -3894.942% |
| Molecular Templates, Inc. | 35.38 Million USD | -1208.125% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -234.759% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 41.33% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -52.377% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -345.283% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | 0.596% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -47.671% |
| MacroGenics, Inc. | 306.82 Million USD | -50.855% |
| RenovoRx, Inc. | 1.46 Million USD | -31472.578% |
| Adicet Bio, Inc. | 207.29 Million USD | -123.283% |
| Prime Medicine, Inc. | 193.85 Million USD | -138.768% |
| Aditxt, Inc. | 44.57 Million USD | -938.294% |
| Adagene Inc. | 115.72 Million USD | -299.947% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10291.432% |
| Quantum-Si incorporated | 298.25 Million USD | -55.19% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 68.883% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -5903.977% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -31.762% |
| SciSparc Ltd. | 11.18 Million USD | -4039.277% |
| Vericel Corporation | 353.65 Million USD | -30.877% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3689.968% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -713.443% |
| Generation Bio Co. | 374.75 Million USD | -23.507% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -81.749% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -191.898% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -35.589% |
| Invivyd, Inc. | 229.18 Million USD | -101.96% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 45.158% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -3703.456% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -153.772% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -2166.226% |
| 2seventy bio, Inc. | 565.42 Million USD | 18.141% |
| ADMA Biologics, Inc. | 329.18 Million USD | -40.607% |
| Clene Inc. | 52.34 Million USD | -784.305% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -688.047% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -256.332% |
| GeoVax Labs, Inc. | 9.28 Million USD | -4885.921% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | 29.195% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -346.722% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -254.987% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -374.469% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -551.935% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -90.826% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 76.386% |
| Evaxion Biotech A/S | 12.88 Million USD | -3491.184% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -83.629% |
| Verve Therapeutics, Inc. | 752.68 Million USD | 38.507% |
| Trevena, Inc. | 40.6 Million USD | -1039.894% |
| Surrozen, Inc. | 46.08 Million USD | -904.457% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -104.932% |
| Cingulate Inc. | 3.49 Million USD | -13156.838% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -2683.415% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -604.603% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -3861.222% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -72.374% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | 38.2% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -267.66% |
| Clearmind Medicine Inc. | 4.32 Million USD | -10603.339% |
| Kronos Bio, Inc. | 213.27 Million USD | -117.018% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -189.675% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5306.788% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -25.608% |
| Statera Biopharma, Inc. | 21.16 Million USD | -2086.4% |
| ImmunityBio, Inc. | 504.45 Million USD | 8.246% |
| Korro Bio, Inc. | 221.66 Million USD | -108.81% |
| Kineta, Inc. | 10.28 Million USD | -4402.033% |
| BioVie Inc. | 25.2 Million USD | -1736.114% |
| Codexis, Inc. | 136.56 Million USD | -238.936% |
| Celularity Inc. | 143.88 Million USD | -221.674% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | 27.15% |
| Celcuity Inc. | 191.21 Million USD | -142.054% |
| Virax Biolabs Group Limited | 5.48 Million USD | -8340.128% |
| Cibus, Inc. | 544.41 Million USD | 14.981% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -267.654% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -2152.989% |
| IN8bio, Inc. | 33.7 Million USD | -1273.087% |
| Kodiak Sciences Inc. | 479.37 Million USD | 3.446% |
| Annexon, Inc. | 297.67 Million USD | -55.49% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -167.53% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -236.697% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -2104.802% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 84.52% |
| Eyenovia, Inc. | 28.77 Million USD | -1508.284% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -100.78% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6307.171% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -659.699% |
| Arcellx, Inc. | 825.13 Million USD | 43.905% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -466.966% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -0.125% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -1405.216% |
| Moolec Science SA | 24.05 Million USD | -1824.446% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -49.248% |
| Geron Corporation | 394.07 Million USD | -17.453% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -355.072% |
| Royalty Pharma plc | 16.38 Billion USD | 97.175% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | 22.205% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -6517.101% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -3748.357% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -104.748% |
| Humacyte, Inc. | 128.22 Million USD | -260.976% |
| Structure Therapeutics Inc. | 482.01 Million USD | 3.976% |
| 89bio, Inc. | 596.26 Million USD | 22.375% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -83.562% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -24919.135% |
| Genelux Corporation | 27.89 Million USD | -1559.391% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -417.716% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -101.742% |
| Notable Labs, Ltd. | 19.54 Million USD | -2268.63% |
| Liquidia Corporation | 120.43 Million USD | -284.331% |
| Mustang Bio, Inc. | 17.74 Million USD | -2508.804% |
| Immunovant, Inc. | 666.71 Million USD | 30.577% |
| Quantum-Si incorporated | 298.25 Million USD | -55.19% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -220.534% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -754.605% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -163.665% |
| Acasti Pharma Inc. | 73.3 Million USD | -531.452% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -10067.518% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -1672.242% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 52.026% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -8818.33% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -1931.755% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -796.952% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -156.158% |
| PepGen Inc. | 143.05 Million USD | -223.556% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1111.121% |
| United Therapeutics Corporation | 7.16 Billion USD | 93.542% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -2312.583% |
| Solid Biosciences Inc. | 164.93 Million USD | -180.621% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -7782.041% |
| Immuneering Corporation | 102.58 Million USD | -351.193% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -10642.512% |
| Silo Pharma, Inc. | 7.74 Million USD | -5875.285% |
| Belite Bio, Inc | 94.64 Million USD | -389.058% |
| XOMA Corporation | 234.3 Million USD | -97.547% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -98.49% |
| Bionomics Limited | 27.64 Million USD | -1574.03% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -15.309% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -331.011% |
| uniQure N.V. | 831.68 Million USD | 44.348% |
| Cassava Sciences, Inc. | 151.66 Million USD | -205.186% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -10291.432% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -68.996% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1087.414% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -11263.64% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -1156.697% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -6307.171% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -13075.463% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -3815.523% |
| Altimmune, Inc. | 210.64 Million USD | -119.737% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 40.498% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -331.011% |
| Compugen Ltd. | 121.33 Million USD | -281.471% |
| Peak Bio, Inc. | 2.59 Million USD | -17726.657% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -168.591% |
| Benitec Biopharma Inc. | 52.21 Million USD | -786.524% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -35.393% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -1231.073% |
| Zura Bio Limited | 100.84 Million USD | -358.985% |
| PolyPid Ltd. | 15.37 Million USD | -2911.02% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -288.02% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -1231.073% |
| Instil Bio, Inc. | 325.63 Million USD | -42.141% |
| argenx SE | 4.54 Billion USD | 89.81% |
| Immunome, Inc. | 148.54 Million USD | -211.602% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -195.046% |
| Verona Pharma plc | 308.12 Million USD | -50.217% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -432.267% |
| Shattuck Labs, Inc. | 159.56 Million USD | -190.074% |
| CervoMed Inc. | 9.97 Million USD | -4541.294% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -145.603% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -3964.401% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -157.994% |
| Moolec Science SA | 24.05 Million USD | -1824.446% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -7466.089% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -167.632% |
| AnaptysBio, Inc. | 452.38 Million USD | -2.313% |
| Design Therapeutics, Inc. | 289.64 Million USD | -59.802% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -535.57% |
| NeurAxis, Inc. | 509.49 Thousand USD | -90745.106% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -8442.894% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1038.968% |
| Achilles Therapeutics plc | 161.45 Million USD | -186.675% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -432.267% |
| 180 Life Sciences Corp. | 5.25 Million USD | -8700.382% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -557.204% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -5306.788% |
| Nutriband Inc. | 7.51 Million USD | -6057.304% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -81.735% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -132.239% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -507.324% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -699.182% |
| MoonLake Immunotherapeutics | 526.54 Million USD | 12.095% |
| Palisade Bio, Inc. | 14.05 Million USD | -3193.866% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -120.097% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 68.291% |
| Neurogene Inc. | 222.57 Million USD | -107.956% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | 28.42% |
| AEON Biopharma, Inc. | 6.84 Million USD | -6661.928% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -2.167% |
| Sesen Bio, Inc. | 189.17 Million USD | -144.671% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -70.25% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -3275.572% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 40.686% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -73.357% |
| Athira Pharma, Inc. | 160.24 Million USD | -188.841% |
| Vaccinex, Inc. | 3.63 Million USD | -12647.287% |
| HCW Biologics Inc. | 28.51 Million USD | -1523.271% |
| XOMA Corporation | 234.3 Million USD | -97.547% |
| Nektar Therapeutics | 398.03 Million USD | -16.285% |
| Arvinas, Inc. | 1.3 Billion USD | 64.521% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -2616.705% |
| Merus N.V. | 458.49 Million USD | -0.951% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -126.483% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -156.85% |
| Rezolute, Inc. | 132.73 Million USD | -248.7% |
| Clene Inc. | 52.34 Million USD | -784.305% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -3001.432% |
| BeyondSpring Inc. | 24.8 Million USD | -1765.745% |
| Synlogic, Inc. | 75.55 Million USD | -512.646% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -3801.99% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -4842.909% |
| Peak Bio, Inc. | 2.59 Million USD | -17726.657% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -164.741% |
| Krystal Biotech, Inc. | 818.35 Million USD | 43.441% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -92.505% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | 36.227% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -12839.097% |
| MannKind Corporation | 475.19 Million USD | 2.598% |
| Ikena Oncology, Inc. | 192.09 Million USD | -140.954% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -3360.849% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -297.167% |
| Gossamer Bio, Inc. | 311.91 Million USD | -48.391% |
| CohBar, Inc. | 16.36 Million USD | -2728.201% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -1216.31% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -6227.464% |
| Legend Biotech Corporation | 1.84 Billion USD | 74.962% |
| Mural Oncology plc | 301.74 Million USD | -53.392% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -1382.794% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -8048.257% |
| Disc Medicine, Inc. | 367.99 Million USD | -25.777% |
| Champions Oncology, Inc. | 26.13 Million USD | -1671.215% |
| REGENXBIO Inc. | 573.97 Million USD | 19.359% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -16991.561% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -199.803% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -3732.975% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -36.12% |
| Vaxart, Inc. | 91.83 Million USD | -404.034% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -672.661% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -212.05% |
| Cellectis S.A. | 334.27 Million USD | -38.467% |
| Longeveron Inc. | 12.17 Million USD | -3700.739% |
| Repare Therapeutics Inc. | 253.9 Million USD | -82.297% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 85.822% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -130.451% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 77.839% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -28383.323% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -66.668% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -183.789% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -233.603% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -1713.549% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.964% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 59.888% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -3689.968% |
| Veru Inc. | 50.59 Million USD | -814.805% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -916.078% |
| Cingulate Inc. | 3.49 Million USD | -13156.838% |
| Passage Bio, Inc. | 150.54 Million USD | -207.452% |
| Context Therapeutics Inc. | 16.06 Million USD | -2781.539% |
| Exicure, Inc. | 11.58 Million USD | -3897.012% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -23.084% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -186.345% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -2549.119% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -39.102% |
| Nuvalent, Inc. | 732.38 Million USD | 36.802% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -2997.24% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -416.843% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -3161.602% |
| OmniAb, Inc. | 401.98 Million USD | -15.142% |
| Anew Medical, Inc. | 19.45 Million USD | -2278.984% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -1631.813% |
| Lipocine Inc. | 23 Million USD | -1912.315% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -231.066% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -51.475% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -451.402% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -280.824% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -5733.069% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 47.539% |
| Ocugen, Inc. | 64.54 Million USD | -617.081% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -271.648% |
| Q32 Bio Inc. | 306.11 Million USD | -51.201% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -10899.382% |
| Alumis Inc. Common Stock | 89.61 Million USD | -416.509% |
| Equillium, Inc. | 50.53 Million USD | -815.998% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -515.538% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1021.431% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -27113.051% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -1670.606% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -618.26% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -12318.566% |
| Dominari Holdings Inc. | 57.55 Million USD | -704.152% |
| Edesa Biotech, Inc. | 8.89 Million USD | -5106.201% |
| vTv Therapeutics Inc. | 11.01 Million USD | -4100.889% |
| Bio-Techne Corporation | 2.81 Billion USD | 83.547% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 50.609% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 42.959% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -66.695% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1009.908% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | 30.668% |
| Nkarta, Inc. | 378.88 Million USD | -22.162% |
| BioCardia, Inc. | 2.98 Million USD | -15395.614% |
| Iterum Therapeutics plc | 26.25 Million USD | -1662.649% |